跳至主要内容
临床试验/NL-OMON50869
NL-OMON50869已完成不适用

Personalized microbial substrates to prevent type 2 diabetes - Personalizedfiber study

niversiteit Maastricht0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Overweight/obese (BMI >= 28 kg/m2 < 40 kg/m2) with insulin resistance
  • (HOMA-IR>2.2) and/or impaired glucose
  • tolerance (IGT: 2h plasma glucose during 75g OGTT 7.8-11.1 mmol/l) and/or
  • impaired fasting glucose (IFG:
  • plasma glucose >= 5.6 mmol/l) aged 30-70 years

排除标准

  • - diabetes mellitus
  • - gastroenterological diseases or major abdominal surgery (allowed i.e.:
  • appendectomy, cholecystectomy)
  • - lactose intolerance and other digestive disorders
  • - cardiovascular disease, cancer, liver or kidney malfunction (determined based
  • on ALAT and creatinine levels,
  • respectively)
  • - disease with a life expectancy shorter than 5 years
  • - abuse of products (alcohol consumption > 15 units/week, or any drugs)
  • - excessive nicotine use defined as >20 cigarettes per day
  • - plans to lose weight or follow a hypocaloric diet
  • - regular supplement of pre- or probiotic products
  • - intensive exercise more than three hours a week
  • - - use of any medication that influences glucose or fat metabolism and
  • inflammation, like i.e. lipid
  • lowering-drugs (e.g. PPAR γ or PPARa (fibrates) agonists), glucose-lowering
  • agents (including all
  • sulfonylureas, biguanides, a-glucosidase inhibitors, thiazolidinediones,
  • repaglinide, nateglinide and insulin),
  • anti-oxidants or chronic corticosteroids treatment.
  • - use of laxation products in the last three months or during the study period-
  • Suikerziekte heeft;
  • - Pregnancy

研究者

相似试验